Literature DB >> 9266970

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism.

D Chauhan1, P Pandey, A Ogata, G Teoh, S Treon, M Urashima, S Kharbanda, K C Anderson.   

Abstract

The stress-activated protein kinases (SAPKs), also known as c-Jun amino-terminal kinases (JNKs), are activated in response to diverse stimuli including DNA damage, heat shock, interleukin-1, tumor necrosis factor-alpha and Fas. Although all these inducers cause apoptosis, whether SAPK/JNK activation is required for apoptosis is controversial. In this study, we demonstrate that ionizing radiation (IR) and dexamethasone (Dex) induce apoptosis in multiple myeloma (MM) derived cell lines, as well as in patient cells. IR-induced apoptosis is associated with activation of SAPK/JNK and p38 kinase, in contrast to Dex-induced apoptosis, which is not associated with activation of stress kinases. Moreover, Dex-induced apoptosis is associated with a significant decrease in the activities of mitogen activated protein kinase (MAPK) and p70S6K, whereas IR-treatment does not alter the activity of these kinases. Both IR and Dex induce poly (ADP ribose) polymerase (PARP) cleavage, a signature event of apoptosis. Finally, interleukin-6 (IL-6) inhibits Dex-induced apoptosis, downregulation of MAP and p70S6K growth kinases and PARP cleavage; in contrast, IL-6 does not inhibit IR-induced apoptosis, activation of SAPK/JNK, and PARP cleavage. Taken together, our findings suggest that SAPK/JNK activation is not required for apoptosis in MM cells, and that there are at least two distinct apoptotic signaling pathways: (i) SAPK/JNK-associated, which is induced by IR and unaffected by IL-6; and (ii) SAPK/JNK-independent, which is induced by Dex, associated with downregulation of MAPK and p70S6K and inhibited by IL-6.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266970     DOI: 10.1038/sj.onc.1201253

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  Multiple myeloma.

Authors:  N Raje; K C Anderson
Journal:  Curr Treat Options Oncol       Date:  2000-04

2.  Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.

Authors:  M A Gertz; M Q Lacy; J A Lust; P R Greipp; T E Witzig; R A Kyle
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  Apoptotic signalling cascade in photosensitized human epidermal carcinoma A431 cells: involvement of singlet oxygen, c-Jun N-terminal kinase, caspase-3 and p21-activated kinase 2.

Authors:  W H Chan; J S Yu; S D Yang
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

4.  A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

Authors:  Peter M Voorhees; Robert F Manges; Pieter Sonneveld; Sundar Jagannath; George Somlo; Amrita Krishnan; Suzanne Lentzsch; Richard C Frank; Sonja Zweegman; Pierre W Wijermans; Robert Z Orlowski; Britte Kranenburg; Brett Hall; Tineke Casneuf; Xiang Qin; Helgi van de Velde; Hong Xie; Sheeba K Thomas
Journal:  Br J Haematol       Date:  2013-02-25       Impact factor: 6.998

5.  Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Authors:  Triona Ni Chonghaile; Kristopher A Sarosiek; Thanh-Trang Vo; Jeremy A Ryan; Anupama Tammareddi; Victoria Del Gaizo Moore; Jing Deng; Kenneth C Anderson; Paul Richardson; Yu-Tzu Tai; Constantine S Mitsiades; Ursula A Matulonis; Ronny Drapkin; Richard Stone; Daniel J Deangelo; David J McConkey; Stephen E Sallan; Lewis Silverman; Michelle S Hirsch; Daniel Ruben Carrasco; Anthony Letai
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

6.  Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis.

Authors:  Rachel Spokoini; Shlomit Kfir-Erenfeld; Eitan Yefenof; Ronit Vogt Sionov
Journal:  Mol Endocrinol       Date:  2010-04-06

7.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.

Authors:  L I Plotkin; R S Weinstein; A M Parfitt; P K Roberson; S C Manolagas; T Bellido
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

8.  Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic intervention.

Authors:  Gwenny Manel Fuhler; Sander Henricus Diks; Maikel Petrus Peppelenbosch; William Garrow Kerr
Journal:  Mol Med       Date:  2011-04-28       Impact factor: 6.354

9.  Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.

Authors:  Bo Cai; Shuiliang Wang; Jingcao Huang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

10.  Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

Authors:  Peter M Voorhees; Qing Chen; George W Small; Deborah J Kuhn; Sally A Hunsucker; Jeffrey A Nemeth; Robert Z Orlowski
Journal:  Br J Haematol       Date:  2008-03-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.